Aveanna Delivers Strong Q2: Revenue Climbs 13.7%, 2026 Guidance Raised
AVAH sits 53% above its 52-week low of $5.93.
Summary
Aveanna Healthcare reported strong Q2 2026 results with revenue up 13.7% to $670.5M and raised full-year guidance, driven by volume growth across all segments and improved free cash flow.
Key Events · Earnings and Guidance · AVAH
-
Q2 Revenue Beats Expectations
Revenue of $670.5 million, up 13.7% year-over-year, driven by 14.8% growth in Home Health & Hospice, 14.0% in Private Duty Services, and 9.4% in Medical Solutions.
-
Adjusted EBITDA Growth
Adjusted EBITDA of $95.4 million, up 8.0% from $88.3 million in Q2 2025, with gross margin of $218.5 million.
-
Raised 2026 Guidance
Full-year 2026 guidance raised to over $2.68 billion in revenue and over $365 million in Adjusted EBITDA, reflecting confidence in continued growth.
-
Strong Cash Flow and Liquidity
Free cash flow of $75.4 million year-to-date, a $38.5 million improvement over 2025, with total liquidity of $432.7 million as of July 4, 2026.
Analysis · AVAH · Industrial Applications And Services
Aveanna delivered Q2 revenue of $670.5 million, up 13.7% year-over-year, with Adjusted EBITDA of $95.4 million, an 8.0% increase. The company also raised its full-year 2026 guidance to over $2.68 billion in revenue and over $365 million in Adjusted EBITDA. Free cash flow improved by $38.5 million to $75.4 million year-to-date, and liquidity stands at $432.7 million. These results demonstrate accelerating growth across all three business segments and improving cash generation, which supports the company's strategic initiatives including the recent Family First Homecare acquisition.
At the time of this filing, AVAH was trading at $9.09 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2B. The 52-week trading range was $5.93 to $10.32. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.